Navigation Links
Neogen Reports Second Quarter Results
Date:12/22/2011

LANSING, Mich., Dec. 22, 2011 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that its revenues for the second quarter of FY 2012, which ended Nov. 30, increased 2.2% from the previous year's second quarter to $44,891,000. Net income for the quarter was $5,237,000, or $0.22 per share, compared to the prior year's second quarter net earnings of $6,110,000, or $0.26 per share.

Year-to-date revenues for the first six months of fiscal year 2012 increased to $90,588,000 from FY 2011's $86,853,000, an increase of 4.3%. Year-to-date net income for the same six-month period was $11,241,000, or $0.47 per share, compared to $11,935,000, or $0.51 per share, in FY 2011.

"While I am pleased to report that we remain solidly profitable, I am not pleased to report that we did not meet the high expectations we expect from ourselves," said James Herbert, Neogen's chief executive officer and chairman. "Going forward, our higher growth should return. Despite the results we are reporting today, the company made solid progress in several fundamental areas during the quarter that we expect to drive future growth."

The second quarter was the 75th consecutive profitable quarter from operations for the company, and the 79th quarter of the past 84 quarters when Neogen reported revenue increases as compared with the previous year.

"Although we made good progress in our efforts to expand our sales and marketing organizations to spur future growth, we fell short of our revenue and income goals for the quarter," said Lon Bohannon, Neogen's chief operating officer. "Significant future opportunities should be realized in the quarters ahead to return Neogen to the growth levels we have come to expect. From growing global markets to expanding worldwide regulations pertaining to food safety, the fundamentals for our business remain solid."

For the second quarter of its 2012 fiscal year, Neogen's percentage of revenues from international sources represented 42% of its total revenues, compared to 43% in last year's second quarter.

"Our balance sheet remains strong, giving us the ability to seize opportunities as the business climate improves and pursue a wide variety of growth strategies," said Steve Quinlan, Neogen's chief financial officer.

Neogen's Animal Safety Division second quarter FY 2012 revenues increased to $22,849,000 from $22,590,000 in the same period last year. For FY 2012's first six months, the Animal Safety Division's sales increased 4.6% over FY 2011 year-to-date to $45,264,000. Strong quarterly revenue growth in the division's animal care lines were offset by decreases in revenues from the company's rodenticide and disinfectant product lines as well as a decline in GeneSeek agricultural genetic test service business.

Strong divisional performers for the quarter included a double-digit increase in sales of veterinary biologics, including a proprietary equine botulism vaccine, and significant sales increases in companion animal products sold through key veterinary distribution channels. Neogen's forensic test kit revenues were up 12% in the second quarter compared with the prior year quarter and the launch of an improved substrate product led to an increase in sales of test reagents. 

Neogen's Food Safety Division's second quarter revenues increased 3.3% to $22,042,000 in FY 2012 from $21,341,000 in FY 2011. Year-to-date, the Food Safety Division's revenues increased 4.0% to $45,324,000 from $43,593,000 in FY 2011. Second quarter increases in sales of Soleris® test systems used to detect spoilage organisms and Neogen's AccuPoint® general sanitation test systems were partially offset by a decline in sales of dehydrated culture media. For both the quarter and year-to-date period, Neogen also achieved high double-digit increases in sales of both food and animal safety products from its Mexican and Brazilian subsidiaries.

Gross margins were 50.5% in the second quarter of FY 2012 compared to 51.2% in the same period a year ago, and were 50.4% for the year-to-date, from 52.1% for the same period a year ago. The change in gross margins for both periods was due to changes in product mix and increases in manufacturing expenses. Operating expenses increased by $1,655,000, or 12.9%, in the second quarter of FY 2012 compared to FY 2011, due primarily to an increase of $1,127,000 in sales and marketing expenses. Neogen previously announced an investment in sales and marketing personnel in order to increase future organic sales growth. On a year-to-date basis, operating expenses were 8.1% over the same period from last year, principally for the same reason.

Neogen's recently released fully quantitative testing methodology for natural toxins is beginning to build sales momentum. The first test launched in the line, Reveal® Q+ for Aflatoxin, is a fully quantitative lateral flow screening test. Aflatoxin is a by-product of mold growth in a wide range of commodities, including corn, and is considered by many to be the most potent, naturally-occurring carcinogen. Because it is a known severe threat to human and animal health, more than 100 countries have established regulatory limits for aflatoxin in commodities intended as human food or animal feed. Follow-up tests in the new testing methodology for two other important natural toxins, deoxynivalenol (DON) and zearalenone, will be launched in Neogen's third quarter.

Neogen also recently launched an even faster method to rapidly and accurately detect yeast and mold in food products. Neogen's new Soleris test detects yeast and mold in 48 hours or less — conventional methods take up to 5 days. Tests for yeast and mold comprise approximately 15% of all microbiological tests performed worldwide.

In the third quarter, Neogen also plans to debut the next generation of molecular diagnostics for foodborne pathogens. The innovative testing platform, to be marketed under the trade name ANSR, offers many advantages over existing rapid testing methodologies, including polymerase chain reaction (PCR), by utilizing a unique isothermal reaction test system that is fast, simple and inexpensive. The single-temperature reaction requires only 10 minutes after incubation to deliver DNA-RNA definitive results.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

  NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED OPERATING DATA
(In thousands, except for per share and percentages) 

 

 

 

  

 Quarter ended Nov. 30 Six months ended Nov. 30 

 20112010 20112010 

 

 

 

 

 

 Revenue

 

 

 

 

  

Food Safety

$22,042

$21,341

 

$45,324

$43,593 

Animal Safety

22,849

22,590

 

45,264

43,260Total revenue44,89143,931 90,58886,853Cost of sales

22,234

21,443

 

44,954

41,598Gross margin

22,657

22,488

 

45,634

45,255Other expenses

 

 

 

 

  

Sales & marketing

8,631

7,504

 

16,734

15,016 

Administrative

4,173

3,714

 

8,185

7,576 

Research & development

1,710

1,641

 

3,221

3,438Total other expenses

14,514

12,859

 

28,140

26,030Operating income

8,143

9,629

 

17,494

19,225Other income (expense)

(6)

(119)

 

(53)

(490)Income before tax

8,137

9,510

 

17,441

18,735Income tax

2,900

3,400

 

6,200

6,800Net income$5,237$6,110 $11,241$11,935Net income per diluted share$0.22$0.26 $0.47$0.51 

 

 

 

 

 

 Other information:

 

 

 

 

  

Shares to calculate per share

23,974

23,729

 

24,001

23,599 

Depreciation & amortization

$1,532

$1,325

 

$2,911

$2,584 

Interest income

26

28

 

48

57 

Gross margin (% of sales)

50.5%

51.2%

 

50.4%

52.1% 

Operating income (% of sales)

18.1%

21.9%

 

19.3%

22.1% 

Revenue increase vs. FY 2011

2.2%

 

 

4.3%

  

Net income decrease vs. FY 2011

-14.3%

 

 

-5.8%

  

 NEOGEN CORPORATION SUMMARIZED CONSOLIDATED BALANCE SHEET DATA
(In thousands) 

 

 

  

 Nov. 30May 31 

 20112011 

 

(Unaudited)

(Audited) 

 

 

 Assets

 

 Current assets

 

  

Cash & investments

$55,606

$56,083 

Accounts receivable

31,869

28,634 

Inventory

36,425

31,994 

Other current assets

6,518

5,791Total current assets

130,418

122,502Property & equipment

28,888

22,340Goodwill & other assets

75,012

74,820Total assets

$234,318

$219,662 

 

 

 Liabilities & Equity

 

 Current liabilities

$18,409

$17,797Long-term debt

 

 Other long-term liabilities

12,783

12,887Equity: Shares outstanding

 

  

23,527 in Nov. & 23,291 in May

203,126

188,978Total liabilities & equity

$234,318

$219,662 

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.

 

 


'/>"/>
SOURCE Neogen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Webcast Alert: Neogen Corporation to Announce 1st Quarter Results
2. Neogen Reports 26% Increase in Revenues
3. Neogen Honored by Forbes; Two Brokerage Firms Initiate Coverage
4. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
5. Neogen Announces New Share Repurchase Program
6. Neogen Reports Best Quarter in Its 26-Year History
7. Neogens BetaStar(R) US Dairy Antibiotic Test Approved by FDA/NCIMS
8. Neogen Named Supplier of Chr. Hansen Probiotics for Swine and Poultry
9. Neogen Names New Senior Science Officer; Added to S&P Index
10. NeoGenomics Schedules its Q4 and Full Year 2008 Earnings Release for March 5, 2009
11. NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... the results of its 2016 Annual General Meeting, which was ... China . At the Annual ... of KPMG Huazhen LLP as the independent auditors of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building ... team building events, new program offerings and company expansion. , This is ... to include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 ... Company, has expanded its customisable SureSeq™ NGS panel range with ... - allowing fast and cost-effective study of variants in familial ... copy number variation (CNV) detection on a single small panel ... and hotspot content. This includes all exons for LDLR ...
Breaking Biology Technology:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):